Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Predicting response to hepatitis C therapy
Thomas S. Oh, Charles M. Rice
Thomas S. Oh, Charles M. Rice
View: Text | PDF
Commentary

Predicting response to hepatitis C therapy

  • Text
  • PDF
Abstract

Current treatment for chronic hepatitis C is expensive, is often accompanied by burdensome side effects, and, sadly, fails in almost half of cases. The ability to predict such failures prior to treatment could save a great deal of pain and expense for the patient with HCV. In this issue of the JCI, Aurora and colleagues describe the development of genetic markers predictive of treatment response based on a study of viral sequence variation (see the related article beginning on page 225). Genome-wide covariation analyses of pretreatment virus sequences from 94 patients showed distinct patterns of mutations strongly associated with the ultimate success or failure of treatment. Such analyses suggest markers predictive of response to therapy and may lead to new insights into the underlying biology of hepatitis C.

Authors

Thomas S. Oh, Charles M. Rice

×

Figure 1

Covariation in HCV.

Options: View larger image (or click on image) Download as PowerPoint
Covariation in HCV.
(A) In the study reported in this issue of the JCI b...
(A) In the study reported in this issue of the JCI by Aurora et al. (8), patients were grouped according to their treatment response. The sequences of the complete HCV open reading frame obtained from each group of patients prior to treatment were aligned and analyzed for covariance. An example covariant pair is shown in each alignment (red arrows). The set of all covariant pairs forms a network in which each node is an amino acid position and each connecting line represents covariance between 2 positions. The networks differ by treatment response class and may be used to generate markers indicative of HCV treatment outcome. (B) Various causes of covariance in HCV (red arrows). (i) Phylogenetic covariance is an artifact of a shared ancestry, but does not reflect any functional relationship. (ii) RNA secondary structure gives rise to nucleotide-level covariance. (iii) Protein-protein interaction residues covary. (iv) Intraprotein covariance may indicate direct residue contact or indirect interaction through the protein. (v) Variation in a shared interaction partner (host or viral) may result in coordinated variation in a pair of residues. (vi) MHC epitopes will covary across hosts with different HLA alleles.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts